These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22119714)

  • 1. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.
    Copland DA; Liu J; Schewitz-Bowers LP; Brinkmann V; Anderson K; Nicholson LB; Dick AD
    Am J Pathol; 2012 Feb; 180(2):672-81. PubMed ID: 22119714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease.
    Raveney BJ; Copland DA; Nicholson LB; Dick AD
    Arch Ophthalmol; 2008 Oct; 126(10):1390-5. PubMed ID: 18852417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
    Commodaro AG; Peron JP; Lopes CT; Arslanian C; Belfort R; Rizzo LV; Bueno V
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2568-74. PubMed ID: 20019358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis.
    Bousquet E; Camelo S; Leroux les Jardins G; Goldenberg B; Naud MC; Besson-Lescure B; Lebreton L; Annat J; Behar-Cohen F; de Kozak Y
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5414-23. PubMed ID: 21666239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC; Rausch M; Meier DP; Foster CA
    Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
    Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study.
    Fu Y; Hao J; Zhang N; Ren L; Sun N; Li YJ; Yan Y; Huang D; Yu C; Shi FD
    JAMA Neurol; 2014 Sep; 71(9):1092-101. PubMed ID: 25003359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine.
    Mansoor M; Melendez AJ
    Rev Recent Clin Trials; 2008 Jan; 3(1):62-9. PubMed ID: 18474015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
    Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
    J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI325-339)-induced arthritis mouse model.
    Yoshida Y; Tsuji T; Watanabe S; Matsushima A; Matsushima Y; Banno R; Fujita T; Kohno T
    Biol Pharm Bull; 2013; 36(11):1739-46. PubMed ID: 23995704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
    Blanc CA; Rosen H; Lane TE
    J Neuroinflammation; 2014 Aug; 11():138. PubMed ID: 25138356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
    Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
    Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.